Cercare Receives FDA Clearance for CBCT Perfusion and Collaborates With Siemens on Acute Stroke Care

May 29, 2026—Cercare Medical, a developer of neuroimaging software, announced FDA 510(k) clearance for the company’s Cone-Beam CT Perfusion (CBCT-P) solution, which is intended to enable qualitative perfusion assessment directly from cone-beam CT data acquired during neurointerventional procedures.

AMPLIFI-1 Trial Launched for Amplifi Vein Dilation System in Distal AVF Creation

May 27, 2026—Amplifi Vascular announced the initiation of the AMPLIFI-1 pivotal trial evaluating the safety and effectiveness of the Amplifi vein dilation system, an investigational technology designed to facilitate distal arteriovenous fistula (AVF) creation for hemodialysis access.

Terumo Neuro’s HydroCoil Embolic System to Treat Ruptured Intracranial Aneurysms Studied in RAGE

May 27, 2026—Terumo Neuro, a wholly owned subsidiary of Terumo Corporation, announced the publication of results from the RAGE study of ruptured aneurysms treated with hydrogel coils.

Microbot’s Liberty Endovascular Robotic System Receives Marketing Clearance in Israel

May 26, 2026—Microbot Medical Inc. announced that its Liberty endovascular robotic system has achieved regulatory marketing clearance from the Israel Ministry of Health’s AMAR Division.

RADIANT Pivotal Trial Approved for Arsenal’s NeoCast Liquid Embolic for Chronic Subdural Hematoma

May 26, 2026—Arsenal Medical announced that the FDA granted investigational device exemption approval for the RADIANT pivotal trial.

Jupiter’s Vertex PE System Evaluated in SPIRARE II Pivotal Trial

May 26, 2026—Jupiter Endovascular announced results from the SPIRARE II pivotal trial of the company’s Vertex pulmonary embolectomy system in the treatment of patients with acute, intermediate-risk pulmonary embolism (PE).

Sentante Endovascular Robotic Platform Receives CE Mark Approval

May 22, 2026—Sentante, a Lithuania-based medical technology company, announced that its flagship endovascular robotic platform has received CE Mark approval.

Nectero EAST System Evaluated for Treating Small- to Medium-Sized AAA

May 20, 2026—Nectero Therapeutics announced the release of 2-year outcomes from the company’s first-in-human (FIH) trial of the investigational Nectero endovascular aneurysm stabilization treatment (EAST) system.